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Abstract
Introduction: We aimed to replicate the strong associations that a recent genome wide association study (GWAS)
has found between 16 single nucleotide polymorphisms (SNPs) and response to anti-tumour necrosis factor (TNF)
treatment in 89 patients with rheumatoid arthritis (RA). This study is very important because, according to
published simulations, associations as strong as the reported ones will mean that these SNPs could be used as
predictors of response at the individual level.
Methods: Disease activity score (DAS28) was evaluated in 151 anti-TNF treated patients with RA of Spanish
ancestry at baseline and every 3 months thereafter. Genotypes of the 16 putative predictor SNPs were obtained by
single-base extension. Association between the relative change in DAS28 and SNP genotypes was tested by linear
regression. In addition, logistic regression was applied to compare genotypes in non-responders (n = 34) versus
good-responders (n = 61) following the EULAR response criteria.
Results: None of the analyses showed any significant association between the 16 SNPs and response to anti-TNF
treatments at 3 or 6 months. Results were also negative when only patients treated with infliximab (66.9% of the
total) were separately analyzed. These negative results were obtained in spite of a very good statistical power to
replicate the reported strong associations.
Conclusions: We still do not have any sound evidence of genetic variants associated with RA response to anti-TNF
treatments. In addition, the possibility we had envisaged of using the results of a recent GWAS for prediction in
individual patients should be dismissed.
Introduction
Anti-tumor necrosis factor (anti-TNF) therapies have
revolutionized the treatment of rheumatoid arthritis
(RA) [1,2]. Three drugs of this type, infliximab, etaner-
cept, and adalimumab, have been used with success in
hundreds of thousands patients with RA around the
world. New drugs targeting TNF are in development or
have been recently approved [3]. The beneficial effects
of these drugs include a better quality of life; control of
inflammation, stiffness, and pain; and slowing progres-
sion to joint erosions and deformity. It seems also that
they are able to decrease cardiovascular risk and overall
mortality of patients with RA [4,5]. However, there is a
significant percentage of patients who do not obtain
these advantageous effects [1-3]. In some of these
patients, this lack of response is primary, from the start
of the treatment, whereas others develop resistance to
treatment after a period of initial response. Unfortu-
nately, there are no useful predictors to forecast what
the clinical response of a specific patient will be. This
has led to an unsatisfactory trial-and-error approach in
the selection of drugs, meaning that some patients will
miss an effective treatment at a critical window of
opportunity [6] and that health service resources will be
wasted. In response to this challenge, multiple lines of
research are looking for predictors of response to anti-
TNF therapies among patient clinical features, synovial
tissue biomarkers, blood proteins, or genetic variants
[7-10]. Very promising, though preliminary, findings
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nucleotide polymorphisms (SNPs) with an important
association with response to treatment were identified
in a recent genome-wide association study (GWAS) [7].
In our view, the most remarkable aspect of these find-
ings was the marked effect size of each SNP, with levels
very rarely found in genetic studies of complex traits.
All showed an odds ratio (OR) of more than 3.5 in the
comparison between patients with good response and
non-responders. Some of these SNPs showed effect sizes
of an OR of more than 10. If confirmed, these effects,
together with minor allele frequencies of more than
12%, will allow the prediction of response to anti-TNF
treatments with great accuracy at the level of the indivi-
dual patient [11]. The limitation of this study was that
only 89 patients were included, and even very significant
results in a study of this size are uncertain. Our objec-
tive has been to provide the necessary replication to
these exciting findings with the expectation that at least
a few of them will be confirmed. This will be a first step
before proceeding to prospective clinical studies to
assess their utility in clinical practice.
Materials and methods
Patients
A group of 151 patients with RA were followed prospec-
tively at the Rheumatology Unit of the Hospital Clinico
Universitario de Santiago to study the efficacy of anti-
TNF therapy. All of them were of European (Spanish)
ancestry. Only patients who were naïve with respect to
biologic treatments were included. Patients were system-
atically evaluated at the initiation of therapy and every 3
months thereafter. Evaluations included painful and
swollen joint counts, visual analog scales of pain, global
health assessments by the patient and the physician, ery-
throcyte sedimentation rate (ESR), C-reactive protein
(CRP), health assessment questionnaire (HAQ), and dis-
ease activity score using 28 joint counts (DAS28). Clini-
cal characteristics are detailed in Table 1. All
participants gave their informed consent for inclusion,
and the study and procedures were approved by the
clinical research ethics committee of Galicia.
Assessment of the efficacy of the treatment
We used the same procedures described in Liu and col-
leagues [7] to make our results comparable. Response to
anti-TNF treatments was assessed with the DAS28 [12].
T h ep r i m a r yo u t c o m ew a st h eq u a n t i t a t i v ev a r i a b l e
relDAS28, which is the relative change in DAS28
between baseline and the time of evaluation. Presented
as a percentage, this variable is calculated as follows:
relDAS28 = DAS28 at baseline - DAS28 at 3 months / DAS28 at ba () s seline 100. ⎡ ⎣ ⎤ ⎦×
A secondary outcome was the European League
Against Rheumatism (EULAR) response classification in
good, moderate, or non-responders [13]. Good respon-
ders have ΔD A S 2 8o fa tl e a s t1 . 2a n dD A S 2 8a t3
months of not more than 3.2; moderate responders have
(a) ΔDAS28 of at least 1.2 and DAS28 at 3 months of
greater than 3.2 or (b) 0.6 < ΔDAS28 ≤ 1.2 and DAS28
at 3 months of not more than 5.1; and non-responders
are those who do not fit into any of these categories.
Genotypes
A total of 16 SNPs from Liu and colleagues [7] were
analyzed (Table 2). Genotypes were obtained by single-
base extension with the SNaPshot Multiplex Kit
(Applied Biosystems, Foster City, CA, USA) and specific
primers and probes (available in Additional file 1). The
genotype call rate was 99.79%, allele frequencies were in
Hardy-Weinberg equilibrium, and concordant results for
the 16 SNPs were obtained in the 21 samples that were
genotyped twice.
Statistical analysis
Comparisons of the clinical characteristics of the RA
patients included in the GWAS and in our study were
done with the Student t test for data available as mean
and standard deviation and with the chi-square test for
contingency tables for frequency data. Analyses of the
relationship between SNPs and treatment response were
done as in Liu and colleagues [7] to make our results
comparable in this aspect. Briefly, linear regression ana-
lysis between genotype data following a genetic additive
model and relDAS28 as the continuous dependent vari-
able was done. A t statistic was derived from the linear
regression and used to calculate the P value of the asso-
ciation. This statistic is robust to deviations from nor-
mality of relDAS28. We also conducted logistic
regression analysis between the groups of responders
and non-responders. ORs and their 95% confidence
intervals (CIs) were obtained using the non-responder
group as the reference. This second analysis will be less
powerful because the phenotype is transformed to a
dichotomous variable and because the sample size is
reduced by exclusion of the moderate responders. Statis-
tical analyses were performed with a customized version
of the Statistica 7.0 program (StatSoft, Inc., Tulsa, OK,
USA). We visually explored the possibility that consid-
eration of all of the SNPs jointly would discriminate
between responder and non-responder patients. This
analysis was done with the Co-Plot algorithm imple-
mented in the Visual Co-Plot software [14,15]. Estima-
tion of the statistical power for the linear regression
analysis was done by transforming the reported P values
and the number of samples in the corresponding
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2). The values of R
2 and the
number of samples in our study were used as input in
the module for the F test in omnibus comparisons by
linear regression of G*Power version 3.0.10 software
[16].
Results
The aim of our study was to replicate the strong asso-
ciation of 16 SNPs with response to anti-TNF therapy
reported in a recent GWAS [7]. Therefore, we used the
same variables and type of analysis. Data from the 151
patients with RA are shown in Table 1. Some of the
characteristics of our study population were different
from those of the patients analyzed in the GWAS [7].
Specifically, our patients showed a lower percentage of
rheumatoid factor positivity, higher positivity for anti-
CCP (anti-cyclic citrullinated peptide) antibodies, and
higher baseline HAQ and DAS28 levels. There were
70.2% of patients with high disease activity at baseline as
assessed by a DAS28 of greater than 5.1. In spite of this
high activity, there were 40.4% and 43.7% of good
responders at 3 and 6 months, respectively, and only
22.5% and 21.8% of non-responders at 3 and 6 months,
respectively. The percentages of responders and non-
responders were similar in the two studies. In contrast,
the proportion of patients treated with each of the three
anti-TNF drugs was different (Table 1). In our cohort,
most patients were treated with infliximab (66.9%), fol-
lowed by etanercept (23.2%) and adalimumab (9.9%).
We also checked that there was a good correlation
between the variable used as primary outcome in our
analysis, relDAS28, and the EULAR response classifica-
tion (Figure 1), allowing for consistency in the analyses.
The relationship between the SNP genotypes and
response to anti-TNF treatment at 3 months was evalu-
ated by linear regression analysis between the genotypes
and the continuous variable relDAS28. There was no
a s s o c i a t i o no fa n yo ft h e1 6S N P sw i t hr e l D A S 2 8a t3
months (Table 2). Secondary analyses showed very simi-
lar results. Comparison of non-responders with good
responders according to the EULAR criteria at 3 months
did not show any significant association (Table 2). The
Table 1 Clinical characteristics of the patients in this study and of those in the report by Liu and colleagues [7]
Variable This study Data from [7] P value
Age in years, mean ± SD 54.2 ± 13.1 57 ± 13.5 0.06
Age in years at diagnosis, mean ± SD 46.2 ± 13.5 47 ± 15 0.3
Women, percentage 84.8 75 0.06
Disease duration in years, mean ± SD 7.8 ± 6.6 8 ± 8 0.4
Current smokers, percentage
a 9.1 15 0.3
Ever smokers, percentage
a 25.0
Rheumatoid factor-positive, percentage 68.9 83.8 0.01
Anti-CCP-positive, percentage
a 86.3 61.9 0.0001
Shared epitope-positive, percentage
a 58.3
Antinuclear antibody-positive, percentage
a 29.8
HAQ at baseline, mean ± SD 1.4 ± 0.7 1.1 ± 0.6 0.0005
DAS28 at baseline, mean ± SD 5.6 ± 1.2 5.2 ± 0.8 0.002
DAS28 ≥ 5.1, percentage 70.2
3.2 ≤ DAS28 > 5.1, percentage 26.5
DAS28 at 12 to 16 weeks, mean ± SD 3.6 ± 1.4 3.7 ± 1.3 0.2
DAS28 at 6 months, mean ± SD 3.5 ± 1.4
Good responders at 12 to 16 weeks, percentage 40.4 34.8 0.6
Non-responders at 12 to 16 weeks, percentage 22.5 25.8 0.6
Good responders at 6 months, percentage 43.7
Non-responders at 6 months, percentage 21.8
Anti-tumor necrosis factor drug
Infliximab, number 101 32 0.01
Etanercept, number 35 39 0.02
Adalimumab, number 15 18 0.05
aData were available for 102 patients for anti-cyclic citrullinated peptide (CCP) antibodies, antinuclear antibody, and shared epitope and for 88 patients for
smoking habits. DAS28, disease activity score using 28 joint counts; HAQ, health assessment questionnaire; SD, standard deviation.
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to rs437943 in the CNTDE1 locus but compared poorly
with the previously reported OR (4.6, 95% CI 1.8 to
12.3). In addition, there was no association of relDAS28
with any of the 16 SNPs at 6 months or of the classifica-
tion in responders and non-responders (Additional file
2). Finally, analysis of patients treated with infliximab,
which represented 66.9% of our study, did not show any
significant association between response and the SNPs
(Additional file 2). Because of the small number of
patients in the etanercept or adalimumab subgroups, no
separate analyses of response to treatment were done.
We also visually explored whether joint consideration of
the 16 SNPs was able to discriminate between the differ-
ent groups of patients according to their response to
treatment, but patients with different responses did not
show any clustering in identifiable groups in this analy-
sis (Figure 2).
To interpret the above results, it was critical to assess
whether our study had enough statistical power to
replicate the previously reported associations. Power
for the weakest association in the GWAS, which cor-
responds to rs928655 (P =3×1 0
-5), was larger than
95% for a P value of 0.002. It is important to remark
that ORs from the GWAS are very likely heavily
biased upwards as a consequence of the winner’s
curse affecting any GWAS and especially those of
small size [17,18]. Therefore, this power estimate is
valuable only in the context of the reported ORs
taken at face value.
Table 2 Relationship of relDAS28 and single-nucleotide polymorphism genotypes and comparison of allele frequencies
between responders and non-responders
Single-nucleotide
polymorphisms
P value of
relDAS28
MAF of responders,
percentage (n/N)
MAF of non-responders,
percentage (n/N)
OR
a(95%
CI)
P value
rs983332 0.6 25.9 (30/116) 27.9 (19/68) 1.11 (0.6-2.0) 0.8
rs928655 0.1 18.9 (23/122) 28.0 (19/68) 0.60 (0.3-1.2) 0.1
rs13393173 0.8 23.8 (29/122) 20.6 (14/68) 0.83 (0.4-1.7) 0.6
rs437943 0.05 38.5 (47/122) 25.0 (17/68) 0.53 (0.3-1.0) 0.06
rs10945919 0.7 27.9 (34/122) 23.5 (16/68) 0.79 (0.4-1.7) 0.5
rs854547 0.3 39.3 (48/122) 36.8 (25/68) 1.12 (0.6-2.1) 0.7
rs854548 0.9 23.0 (28/122) 23.5 (16/68) 1.03 (0.5-2.0) 0.9
rs854555 0.6 35.2 (43/122) 38.2 (26/68) 1.14 (0.6-2.0) 0.7
rs868856 0.6 32.8 (40/122) 36.8 (25/68) 1.19 (0.6-2.0) 0.6
rs7046653 0.5 32.0 (39/122) 36.8 (25/68) 1.23 (0.7-2.5) 0.5
rs2814707 0.8 25.4 (31/122) 29.4 (20/68) 1.22 (0.6-2.5) 0.6
rs3849942 0.4 23.0 (28/122) 29.4 (20/68) 1.41 (0.7-2.5) 0.3
rs774359 0.2 26.2 (32/122) 36.8 (25/68) 1.64 (0.8-3.3) 0.1
rs6138150 0.5 14.0 (17/122) 14.7 (10/68) 0.94 (0.4-2.2) 0.9
rs6028945 0.9 12.3 (15/122) 13.2 (9/68) 1.09 (0.5-2.5) 0.9
rs6071980 0.9 18.9 (23/122) 16.2 (11/68) 0.83 (0.4-2.0) 0.6
aOdds ratios (ORs) were calculated as in Liu and colleagues [7], taking the allele associated with the non-responders in that report as the numerator of the odds,
and the non-responder odds as the numerator of the OR. CI, confidence interval; MAF, minor allele frequency; n, number of minor alleles; N, total numbero f
alleles; relDAS28, relative change in disease activity score using 28 joint counts between baseline and time of evaluation.
Figure 1 Good correlation between outcome variables: EULAR
(European League Against Rheumatism) response classification
and relDAS28. Medians, interquartile ranges, and non-outlier ranges
are represented as dots, boxes, and whiskers, respectively. Empty
dots represent outliers. relDAS28, relative change in disease activity
score using 28 joint counts between baseline and time of
evaluation.
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There is a great need of good predictors for RA
response to the anti-TNF treatments [1-3,9]. The devel-
opment and approval of new effective drugs for RA add
to this urgency [3]. The recent GWAS from Liu and
colleagues [7] was especially remarkable because it
showed such strong associations that, according to pub-
lished simulations [11], they could be used for predic-
tion in individual patients. This is a characteristic that
has not been found in any of the previous studies. How-
ever, the size of the study implied that results should be
replicated before they could be taken at face value, as
already acknowledged by the authors. We have tried to
provide here the needed replication in the expectation
that some of them will be confirmed and that validation
in prospective studies will soon follow.
Unfortunately, in spite of the moderately larger sample
size of our study and the corresponding very good
power to detect this type of strong association, none of
the associations was replicated. These results make it
very unlikely that any of the 16 SNPs could have an
association as strong as suggested by the previous
GWAS [7]. It is possible that the differences between
the patients with RA in the two studies could have had
an effect on the lack of replication, but these differences
were not large enough to completely explain the very
divergent results. In addition, patients in the GWAS
were predominantly of European ancestry as were all of
the patients in our study. Therefore, it seems more
likely that the original strong associations were due to
random variation of allele frequencies in a study includ-
ing more than 300,000 SNPs and to the heavy bias char-
acteristic of GWASs of small sample size [17,18]. This
p o s s i b i l i t yw a sa l r e a d yc o n s i d e r e db yu sb e f o r eb e g i n -
ning this study, but we judged that some SNPs would
be replicated given that they showed low P values, five
of them with P values of less than 10
-6 [7], and low P
values are the best indication of the reproducibility of
results [19].
Conclusions
Our negative results imply that we still do not have any
strong evidence supporting a significant role of genetic
variation in the response to anti-TNF treatments. In
addition, our results imply that none of the SNPs in our
study will be useful as individual predictors of response
to anti-TNF therapy, but do not exclude a weaker
association.
Additional file 1: Primers and probes used for genotyping. List of
primers and probes used for genotyping the 16 SNPs included in the
study.
Additional file 2: Details of some comparisons of response to
treatment. A table a table with the analyses done after 6 months of
treatment and a table with the results of analyzing treatment response
of patients receiving Infliximab at 3 months.
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